Previous 10 | Next 10 |
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2 PR Newswire TEL AVIV, Israel , April 26, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company...
Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt PR Newswire TEL AVIV, Israel , Jan. 11, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage bio...
Galmed announces positive results of Phase 1 study of Amilo-5MER Single and multiple escalating dose results with excellent safety profile and tolerability Submission of an IND for mild to moderate ulcerative colitis is planned in 2022 PR Newswire TEL AVIV, Isr...
The following slide deck was published by Galmed Pharmaceuticals Ltd. in conjunction with this event. For further details see: Galmed Pharmaceuticals (GLMD) Investor presentation - Slideshow
Galmed Pharmaceuticals Ltd. (GLMD) Q3 2021 Earnings Conference Call November 8, 2021 08:30 ET Company Participants Allen Baharaff - President and Chief Executive Officer Yohai Stenzler - Chief Financial Officer Liat Hayardeny - Chief Scientific Officer Vlad Ratziu - Professor, Hepatology, Sor...
The following slide deck was published by Galmed Pharmaceuticals Ltd. in conjunction with their 2021 Q3 earnings call. For further details see: Galmed Pharmaceuticals Ltd. 2021 Q3 - Results - Earnings Call Presentation
Pioneer Power Solutions (NASDAQ:PPSI) +46% launches E-Boost - smart, mobile EV charging solutions Autolus Therapeutics (NASDAQ:AUTL)+26% on securing $250M strategic funding from Blackstone The Trade Desk (NASDAQ:TTD) +23% on Q3 earnings. Volta(NYSE:VLTA) +19%. Gaotu Techedu (NYSE:GO...
Galmed (NASDAQ:GLMD): Q3 GAAP EPS of $0.31 beats by $0.67. Cash and cash equivalents, restricted cash and marketable debt securities totaled $42.0M as of September 30, 2021, Shares +12.47% PM Press Release For further details see: Galmed EPS beats by $0.67
Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results - Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m. PT - PR Newswire TEL AVIV, Israel , Nov. 8, 2021 ...
Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement PR Newswire -- Updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Galmed Pharmaceuticals Ltd. Website: